Study Title
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma (NCT01522664)
Trial Description
This multicenter, open-label study will assess the safety and pharmacokinetics of DEDN6526A (also known as RG7636 or RG-7636) in patients with metastatic or unresectable melanoma. Cohorts of patients will receive escalating doses of DEDN6526A by intravenous infusion on Day 1 of each 21-day cycle. In the absence of disease progression or unacceptable toxicity, patients may continue to receive DEDN6552A for up to 17 cycles (1 year). This trial is sponsored by Genentech/Roche.
Study Data
- Condition: Melanoma
- Interventions:
- Drugs used in this trial
- DEDN6526 (ARG7636; RG-7636)
- Drugs used in this trial
- Enrollment: 53
- Start: March 2012
- Estimated Completion: April 2015
- Last verified: April 2015
Study Schematic
Click here to Return to Drug map
Last Editorial review: July 7, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.